Maxigen Biotech Inc.
Maxigen Biotech Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Taiwan (TW) and operates across various regions globally. Founded in 2000, the company has established itself as a leader in the development and production of innovative biopharmaceuticals, focusing on high-quality products that cater to diverse medical needs.
Specialising in the manufacture of biologics and biosimilars, Maxigen Biotech is recognised for its commitment to research and development, ensuring that its offerings meet stringent regulatory standards. The company’s unique approach to bioprocessing and quality assurance has positioned it favourably in the competitive landscape, earning accolades for its contributions to healthcare. With a strong emphasis on sustainability and patient-centric solutions, Maxigen Biotech continues to advance its mission of improving global health outcomes.
-16 vs industry average
Maxigen Biotech Inc.’s score of 22 is lower than 36% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Maxigen Biotech Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Maxigen Biotech Inc.'s reported carbon emissions
Maxigen Biotech Inc., headquartered in Taiwan and operating in the Pharmaceutical Preparation Manufacturing industry, reported total carbon emissions of approximately 2.1 million kg CO2e for 2024. This figure includes Scope 1 emissions of about 142,494 kg CO2e and Scope 2 emissions of approximately 1.94 million kg CO2e. For 2023, the company's total emissions were around 2.08 million kg CO2e, with Scope 1 emissions at approximately 130,738 kg CO2e and Scope 2 emissions at about 1.95 million kg CO2e. Maxigen Biotech Inc. currently discloses data for Scope 1 and Scope 2 emissions. The company has indicated missing data points for Scope 3, specifically "purchased goods and services". At present, there is no information available regarding specific reduction targets or participation in initiatives like the Science Based Targets initiative (SBTi).
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Maxigen Biotech Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Maxigen Biotech Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Maxigen Biotech Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project